The Health & Fitness Association released a statement about the Trump Administration's decision that Medicare would cover GLP-1 medications starting as soon as early 2026.
Statement from Mike Goscinski, Chief of Staff, Health & Fitness Association:
"Yesterday’s announcement by the Trump Administration expanding Medicare coverage for GLP-1 medications is an important step toward addressing obesity and chronic disease among older Americans.
"This move builds on recent progress by the Centers for Medicare & Medicaid Services (CMS), which—beginning in 2026—will reimburse physicians for conducting physical activity and nutrition assessments during patient visits, a policy the Health & Fitness Association and our partners at the Physical Activity Alliance strongly advocated for. Together, these efforts signal a meaningful shift toward prevention and lifestyle-based care in our nation’s health system.
"To fully realize their impact, these advances must go hand-in-hand. GLP-1 medications are most effective when paired with structured exercise and behavior change. The next step is clear: Medicare should cover evidence-based physical activity programs and interventions delivered through trusted community partners like fitness centers, studios, and wellness facilities.
"Beyond weight management, regular physical activity—particularly strength training and balance-focused exercise—plays a vital role in preventing falls, the leading cause of injury and loss of independence among older adults. Expanding access to exercise-based prevention programs would not only improve quality of life but also reduce the substantial medical costs associated with fall-related injuries and hospitalizations.
"By connecting medical treatment to physical activity prescriptions and community-based support, we can help more Americans not only lose weight but also gain strength, mobility, and independence—the hallmarks of healthy aging.
The Health & Fitness Association stands ready to work with CMS, HHS, and policymakers to ensure exercise is recognized—and reimbursed—as essential medicine.”